BioSpace News Archive

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: ^NBI).

Dr. Bronner’s Celebrates Historic Victory for Hemp Movement in the U.S.

Ionis Pharmaceuticals, Inc. and its Board of Directors announced today that, effective January 2020, Ionis’ founder and CEO, Stanley T. Crooke, M.D., Ph.D., will be transitioning from chief executive officer to executive chairman of Ionis’ board of directors.

Bruker Corporation has been advised that former board member, Mr. Joerg C. Laukien, has authorized a block sale of Bruker shares as part of his retirement planning and portfolio diversification.

The Competition Bureau announced today that it is closing an investigation into allegations of abuse of dominance by certain brand name drug manufacturers including Celgene Inc., Pfizer Canada Inc. and Sanofi-Aventis Canada Inc.

Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 8, 2019.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Michael C. Greiner, Executive Vice President and Chief Financial Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Tuesday, January 8, 2019 in San Francisco, CA.

Today, Bruce Linton, Chairman & Co-CEO, Canopy Growth Corporation, the world’s largest diversified hemp and cannabis company, (TSX: WEED) (NYSE: CGC) commented on the passage of the Farm Bill, containing the language of the Hemp Farming Act of 2018.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental Biologics License Application (sBLA) for KEYTRUDA

PTC Therapeutics, Inc. today announced that on December 17, 2018 it approved non-statutory stock options to purchase an aggregate of 24,500 shares of its common stock to 5 new employees.